Akebia Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Akebia Therapeutics

14/03/2024 22:23

* Akebia Therapeutics Inc  AKBA.OQ  reported quarterly
breakeven
results​​ per share for the quarter ended in December, higher
than the same quarter last year, when the company reported EPS
of -4 cents.  The mean expectation of three analysts for the
quarter was for a loss of 4 cents per share. Wall Street
expected results to range from -6 cents to -3 cents per share.
    * Revenue rose 1.8% to $56.20 million from a year ago;
analysts
expected $55.39 million. 
    * Akebia Therapeutics Inc's reported EPS for the quarter was
breakeven results​.
    * The company reported quarterly net income of $614
thousand.
    * Akebia Therapeutics Inc shares had risen by 13.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $4.00 

This summary was machine generated from LSEG data March 14 at
10:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.04          0.00           Beat
 Sep. 30 2023      -0.08          -0.08          Met
 Jun. 30 2023      -0.02          -0.06          Missed
 Mar. 31 2023      -0.15          -0.14          Beat